BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21630262)

  • 21. Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization.
    Wu GD; He Y; Chai NN; Toyoda M; Dunn R; Kehry MR; Klein AS; Jordan SC
    Transpl Immunol; 2008 Jul; 19(3-4):178-86. PubMed ID: 18595710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
    Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
    Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas.
    Martorelli D; Guidoboni M; De Re V; Muraro E; Turrini R; Merlo A; Pasini E; Caggiari L; Romagnoli L; Spina M; Mortarini R; Gasparotto D; Mazzucato M; Carbone A; Rosato A; Anichini A; Dolcetti R
    Clin Cancer Res; 2012 Aug; 18(15):4080-91. PubMed ID: 22705988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
    Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Graft-versus-leukemia effect by lymphocytes from the first donor after second cord blood transplantation in a patient with T-lymphoblastic lymphoma].
    Nagai K; Hashimoto H; Itoh K; Matsushita A; Shimoji S; Kimura T; Inoue D; Mori M; Nagai Y; Tabata S; Yanagida M; Takahashi T
    Rinsho Ketsueki; 2010 Jun; 51(6):413-21. PubMed ID: 20622488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
    Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
    Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donors with HLA-B*58:01/TNFα − 308A haplotype are unfavorable to haploidentical hematopoietic stem cell transplantation in acute lymphoblastic leukemia.
    Yang L; Chen X; Liu H; Chen Y; Zhao Y; Bu D; Zhu P
    Transpl Immunol; 2015 Mar; 32(2):92-8. PubMed ID: 25545232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1.
    Kasai M; Akatsuka Y; Emi N; Taji H; Kohno A; Abe A; Tanimoto M; Kodera Y; Saito H
    Int J Hematol; 1999 Feb; 69(2):112-8. PubMed ID: 10071461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphoblastic lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
    Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
    N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
    Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
    Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.
    van Besien KW; de Lima M; Giralt SA; Moore DF; Khouri IF; Rondón G; Mehra R; Andersson BS; Dyer C; Cleary K; Przepiorka D; Gajewski JL; Champlin RE
    Bone Marrow Transplant; 1997 May; 19(10):977-82. PubMed ID: 9169641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.
    Jahn L; Hombrink P; Hassan C; Kester MG; van der Steen DM; Hagedoorn RS; Falkenburg JH; van Veelen PA; Heemskerk MH
    Blood; 2015 Feb; 125(6):949-58. PubMed ID: 25414443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
    Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
    Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
    de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
    J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human leucocyte antigen-Cw-specific cytotoxic T lymphocytes generated from naive cord blood used for cord blood stem cell transplantation.
    Yazaki M; Takahashi T; Mizutani K; Ito Y; Wakiguchi H; Inoue M; Kawa K; Kato K; Kato T; Saito H; Togari H
    Br J Haematol; 2002 Jun; 117(4):893-8. PubMed ID: 12060128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.